|
|
 |
|
Viewing report
|
|
|
|
Premium Company Profile: Depomed
Datamonitor, Nov 2007, Pages: 51
Introduction
Depomed is a specialty pharmaceutical company engaged in the development and commercialization of products that are based on its oral drug delivery technologies. Depomeds business strategy is using its proprietary drug delivery technology AcuForm to potential product candidates of its own and other pharmaceutical companies.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Depomeds marketed products Glumetza and Proquin are related to indications Type II Diabetes and urinary tract infections respectively. Depomed derives its revenues from sales of its products, royalties and license and collaboration fees. Depomeds current operating plan focuses on maximizing the revenues through license and collaboration arrangements with other pharma and biotech companies and commercializing of its existing product portfolio. The companys total revenues increased at a CAGR of 54.8% during 2002-2006, from $1.7 million to $9.6 million. The companys biggest contributor to revenue growth during 2002-2006 was revenues from license and collaboration growing at a CAGR of 22.3% during 2002-2006.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to companys adjusted five year financial data along with key ratios and market capitalization
Customers who bought this item also bought
Depomed, Inc. - SWOT Analysis
Depomed, Inc. - Financial and Strategic Analysis Review
DepoMed, Inc.
Depomed Inc-Therapeutic Competitors
DEPOMED - World'Vest Base Dossier
Depomed Inc & Solvay Pharmaceuticals, Inc Licensing Agreement Call - DepoMed, Inc., - Earnings Transcript
Canaccord Adams Global Growth Conference - DepoMed, Inc., - Earnings Transcript
Poland 2002-2006: Midyear Summary
Cubist Pharmaceuticals Inc: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile
Viropharma Incorporated: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile
DepoMed Inc.-Financial Company Report
DEPOMED - World'Vest Base Business Risk
|
|
|
|
